B cells inhibit induction of T cell-dependent tumor immunity

被引:347
作者
Qin, ZH
Richter, G
Schüler, T
Ibe, S
Cao, XT
Blankenstein, T
机构
[1] Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany
[2] Second Mil Med Univ, Shanghai 200433, Peoples R China
关键词
D O I
10.1038/nm0598-627
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cytotoxic T lymphocyte (CTL) mediated tumor immunity against major histocompatibility antigen (MHC) class I-positive but class Ii-negative tumors often requires help from CD4(+) T cells. These CD4 cells are activated by MHC class Ii-positive cells that present tumor derived antigens(1,2). Considering that different antigen presenting cells, such as B cells, macrophages and dendritic cells compete for antigen and influence the outcome of an immune response(3-13), we analyzed tumor immunity in B cell-deficient mice(14). These mice appear normal with regard to T cell immunity and tolerance to some pure foreign antigens(15-19), We show here that the low immunogenicity of tumors is caused by B cells whose presence in the priming phase results in disabled CD4(+) T cell help for CTL mediated tumor immunity. Instead, in the presence of B cells, a non-protective humoral immune response is induced. Our results may explain the enigmatic observation that tumor-reactive antibodies occur frequently in cancer patients(20).
引用
收藏
页码:627 / 630
页数:4
相关论文
共 35 条